



Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly

¹ L.Peterson, ² L.Clower

^{1,2} University of Pittsburgh School of Medicine, Pennsylvania, United States of America

Correspondence : drpeterson3958482@gmail.com

Article History :

Received date : 2015/10/19

Revised date : 2015/11/08

Accepted date : 2015/12/15

Published date : 2016/01/26



Copyright: © 2016 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction

The use of antimuscarinic drugs to manage overactive bladder (OAB) in elderly patients raises significant concerns about cognitive impairment. This review synthesizes the evolving evidence on the differential cognitive effects of these medications and the role of newer therapeutic alternatives.

Methods

This abstract is based on a literature review synthesizing findings from clinical trials, systematic reviews, and meta-analyses. The review examined the association between various antimuscarinic agents and cognitive function in older adults treated for OAB.

Results

The evidence demonstrates a statistically significant association between the initiation of bladder antimuscarinics and cognitive decline, particularly in patients with pre-existing mild cognitive impairment (MCI). Oxybutynin is consistently associated with memory deterioration due to its high propensity to cross the blood-brain barrier. In contrast, newer, more M3-selective agents like darifenacin demonstrate a lower risk of cognitive side effects. Furthermore, mirabegron, a beta-3 adrenergic agonist, has emerged as a safe alternative, showing no adverse effects on cognitive function compared to placebo.

Discussion

The cognitive risk from antimuscarinics is linked to their ability to penetrate the central nervous system,

a risk heightened by age-related physiological changes like increased blood-brain barrier permeability. The differing pharmacological profiles across agents necessitate careful, individualized risk-benefit assessments. The development of more selective antimuscarinics and non-antimuscarinic agents like mirabegron marks a crucial shift towards safer OAB management in vulnerable elderly patients.

Conclusion

The management of OAB in the elderly requires cautious drug selection to preserve cognitive function. While older agents like oxybutynin pose a significant cognitive risk, newer selective antimuscarinics and alternative drug classes like mirabegron provide effective and safer options. Prioritizing cognitive safety is essential when creating treatment plans for this vulnerable population.

Keywords

Overactive Bladder, Antimuscarinic Drugs, Cognitive Impairment, Elderly, Oxybutynin, Mirabegron.

INTRODUCTION

The management of overactive bladder (OAB) in elderly patients using antimuscarinic drugs has garnered significant attention due to concerns about cognitive functions and potential impairment. This literature review explores the evolving understanding of the effects of antimuscarinic therapy on cognitive decline, particularly in older populations susceptible to cognitive impairment.

In 2008, Kay and Ebinger highlighted the differential cognitive effects of antimuscarinic agents, noting that while oxybutynin was associated with memory deterioration, darifenacin showed a relative selectivity for the M3 receptor that minimized cognitive impact (G Kay & Ebinger, 2008). This foundational study set the stage for understanding how specific pharmacological properties of these medications can influence cognitive outcomes.

Yamada et al. (2012) further characterized the bladder selectivity of antimuscarinic agents, emphasizing the importance of understanding the side effects, particularly on the central nervous system (CNS), in the geriatric population. Their findings indicated that the permeability of the blood-brain barrier increases with age, which may heighten the risk of cognitive side effects from these medications (Yamada et al., 2012).

Tomaszewski (2014) expanded on these concerns by discussing the vulnerability of older adults to antimuscarinic side effects due to age-related changes in cholinergic receptor density. He underscored the need for careful evaluation of individual drug properties and concurrent medications, as many commonly prescribed drugs possess antimuscarinic properties that could exacerbate cognitive impairment (Tomaszewski, 2014).

In 2016, Chen et al. provided practical insights into the treatment of OAB, cautioning against prescribing antimuscarinics to frail elderly patients due to the high incidence of cognitive impairment associated with these drugs, particularly oxybutynin. They recommended starting with lower doses to mitigate adverse effects while balancing treatment efficacy (Chen et al., 2016).

Moga et al. (2007) contributed to this discourse by presenting evidence of a statistically significant association between the initiation of antimuscarinics and cognitive decline in older adults. Their study suggested that patients with mild cognitive impairment (MCI) may experience heightened sensitivity to the cognitive effects of these medications (Claudia Moga et al., 2007).

In a systematic review and meta-analysis, Vouri et al. (2007) examined adverse events related to antimuscarinic use in older adults, highlighting the need for a comprehensive understanding of safety outcomes across different antimuscarinic agents. This study underscored the importance of evaluating the risk-benefit ratio of these medications in the elderly population (Martin Vouri et al., 2007).

Griebeling et al. (2000) introduced mirabegron as an alternative to traditional antimuscarinics, suggesting that it may offer a safer profile regarding cognitive function in elderly patients. Their phase IV study provided insights into the efficacy and tolerability of mirabegron, marking a potential shift in treatment paradigms for OAB in older adults (L. Griebeling et al., 2000).

Overall, this literature review synthesizes critical findings from these studies, emphasizing the need for cautious selection of antimuscarinic therapies in elderly patients to mitigate cognitive risks while effectively managing OAB. The evolving evidence highlights the complexities of treating this condition in a vulnerable population, calling for ongoing research and clinical vigilance.

LITERATURE REVIEW

The article "Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin" by Kay and Ebinger (G Kay & Ebinger, 2008) provides a critical examination of the cognitive implications associated with the use of antimuscarinic drugs in managing overactive bladder (OAB), particularly in elderly patients. The authors emphasize the heightened concern regarding cognitive impairment that may arise from antimuscarinic therapy, especially in individuals with pre-existing comorbid conditions that compromise central nervous system (CNS) function.

The article highlights a significant distinction among various antimuscarinic agents in their propensity to penetrate the blood-brain barrier and their interaction with the

M1 muscarinic receptor, which is crucial in cognitive processes. The findings indicate that oxybutynin, a commonly prescribed antimuscarinic, has been consistently linked to cognitive decline, particularly deterioration in memory functions. This association has been formally recognized by the US Food and Drug Administration, which has issued warnings regarding the cognitive risks associated with oxybutynin-containing products. Conversely, darifenacin is presented as a safer alternative, as studies cited by the authors indicate that it does not impair cognitive functions or memory in the same manner as oxybutynin.

Additionally, the article discusses the implications of these findings for clinical practice, underscoring the necessity for careful selection of OAB medications to mitigate the risk of CNS-related side effects. The authors advocate for a more nuanced understanding of the pharmacological profiles of antimuscarinic agents, suggesting that clinicians should prioritize medications like darifenacin that demonstrate a lower risk of cognitive impairment.

The article "Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of In Vivo Drug-Receptor Binding" by Yamada, Kuraoka, Osano, and Ito (Yamada et al., 2012) provides a comprehensive examination of the use of antimuscarinic agents in managing lower urinary tract symptoms (LUTS) associated with overactive bladder (OAB) in the elderly population. The authors underscore the prevalence of LUTS in geriatric patients and the significance of selecting appropriate pharmacological treatments that minimize adverse effects, particularly cognitive dysfunction.

A critical aspect of the article is its focus on the anticholinergic side effects that are prevalent among antimuscarinic drugs. These side effects, which include dry mouth, constipation, somnolence, and blurred vision, are particularly concerning in elderly patients who may already be experiencing cognitive decline. The article highlights that dry mouth, the most frequently reported side effect, significantly impacts the quality of life of these individuals (Yamada et al., 2012). This is particularly relevant given the elderly population's susceptibility to adverse drug reactions due to physiological changes, such as increased blood-brain barrier permeability.

Moreover, the authors present compelling evidence from clinical studies indicating that elderly individuals show heightened cognitive sensitivity to scopolamine, a common antimuscarinic agent. They also note a reduction in the density of brain muscarinic receptors with age, which may exacerbate the cognitive side effects of these medications (Yamada et al., 2012). This finding is critical, as it suggests that the cognitive functions of elderly patients may be adversely affected by standard doses of antimuscarinic drugs, necessitating a careful evaluation of their use.

The article emphasizes the importance of bladder selectivity in the pharmacological management of OAB. The authors advocate for a thorough assessment of the selectivity profiles of antimuscarinic agents to optimize therapeutic outcomes while minimizing cognitive side effects. This approach is essential for ensuring that the treatment of LUTS does not inadvertently compromise the cognitive health of elderly patients.

The article "Postmenopausal overactive bladder" by Jacek Tomaszewski (Tomaszewski, 2014) provides a comprehensive examination of the cognitive implications associated with the use of antimuscarinic drugs in the treatment of overactive bladder (OAB) in elderly patients. The author highlights the heightened vulnerability of older individuals to cognitive side effects due to age-related alterations in cholinergic receptor availability, which are crucial for cognitive functions such as short-term memory. This vulnerability is particularly relevant in the context of pharmacological treatments that employ anticholinergic mechanisms, as these can exacerbate underlying cognitive deficits.

Tomaszewski emphasizes the importance of understanding the pharmacokinetic properties of antimuscarinic agents, particularly their affinity for central nervous system (CNS) muscarinic receptors and their ability to cross the blood-brain barrier. The article notes that as the permeability of the blood-brain barrier increases with age, the risk of cognitive impairment from antimuscarinic drugs also escalates. This is a critical insight, as it underscores the need for careful consideration of medication regimens in elderly patients, who often require multiple drugs, many of which possess antimuscarinic properties themselves.

The discussion on specific medications is vital for clinical practice. Oxybutynin is identified as having a significant potential for cognitive impairment in cognitively intact older patients due to its high propensity to penetrate the blood-brain barrier. In contrast, newer agents such as solifenacin, darifenacin, trospium, fesoterodine, and tolterodine are presented as safer alternatives with no significant cognitive adverse effects reported in this demographic. This distinction is crucial for healthcare providers when prescribing treatments for OAB, particularly in elderly patients who may already be experiencing cognitive decline.

Moreover, the article details the cognitive effects that may arise from antimuscarinic use, including impaired attention, delayed memory, altered visuospatial orientation, dizziness, and somnolence. These potential adverse outcomes warrant a careful evaluation of the risk-benefit ratio when considering antimuscarinic therapies for OAB in the elderly population.

The article "Practical points in the medical treatment of overactive bladder and nocturia in the elderly" by Chen et al. (Chen et al., 2016) provides a thorough examination of the implications of antimuscarinic therapy in the management of overactive bladder (OAB) among elderly patients. The authors highlight that antimuscarinic drugs, despite being the most common treatment option, are associated with a significant incidence of adverse effects (AEs), particularly cognitive impairment, which poses a serious concern for this demographic.

A critical evaluation of the material reveals that the authors effectively underscore the prevalence of AEs from antimuscarinic therapy, reporting that 46.8% of patients experience such effects. This statistic raises important considerations for clinicians who must weigh the benefits of symptom management against the potential cognitive decline that can accompany these medications. The article emphasizes the necessity for caution when prescribing these drugs to frail elderly patients, as their vulnerability to cognitive impairment is markedly heightened.

The authors specifically point out that oxybutynin, one of the most commonly prescribed antimuscarinics, is linked to a high incidence of cognitive impairment and is therefore not recommended for frail older patients. This assertion is particularly relevant given that oxybutynin was found to significantly decrease

cognitive functions related to attention, such as power and continuity. This finding is critical as it suggests that while oxybutynin may offer symptomatic relief for OAB, the cognitive costs may outweigh the benefits, especially in a population that already faces challenges with cognitive health.

Moreover, the article advocates for a more cautious approach to dosing in elderly patients. The recommendation to initiate treatment with a low dose of antimuscarinics and to gradually escalate to an effective level is a prudent strategy that acknowledges the delicate balance between managing OAB symptoms and preserving cognitive function. This approach allows for individualized patient care, which is essential in geriatric medicine.

The article "Bladder Antimuscarinics and Cognitive Decline in Elderly Patients" by Moga, Abner, Wu, and Jicha (Claudia Moga et al., 2007) presents a critical examination of the relationship between the initiation of bladder antimuscarinic drugs and cognitive function in older adults. The authors provide compelling evidence that the use of these medications is statistically associated with a decline in cognitive abilities among patients aged 65 years and older.

The study is particularly noteworthy for its focus on mild cognitive impairment (MCI), a condition that affects a significant portion of the elderly population. The authors found that individuals with MCI may exhibit heightened sensitivity to the cognitive side effects of antimuscarinic drugs. This finding is crucial, as it suggests that the risks associated with these medications may be more pronounced in a vulnerable subset of the elderly, thereby necessitating careful consideration when prescribing antimuscarinics for overactive bladder management in this demographic.

The methodology employed in the study is robust, utilizing various cognitive measures to assess the impact of antimuscarinic initiation. The statistical analyses are thorough, providing a clear link between medication use and cognitive decline. However, the study could benefit from a more detailed exploration of the underlying mechanisms through which antimuscarinic drugs may influence cognitive function. Understanding these mechanisms could inform clinical

decisions and lead to the development of alternative treatments that mitigate cognitive risks.

Moreover, while the study establishes a correlation, it does not delve deeply into the potential confounding factors that may influence cognitive decline in older adults, such as comorbidities or polypharmacy. Future research could expand on these findings by controlling for such variables to better isolate the effects of antimuscarinics on cognitive function.

The systematic review and meta-analysis conducted by Vouri, Kebodeaux, Stranges, and Teshome (Martin Vouri et al., 2007) provides a comprehensive examination of the adverse events and treatment discontinuations associated with antimuscarinic drugs in older adults suffering from overactive bladder (OAB). The authors highlight the significant impact of OAB on the quality of life in this population and emphasize the need for a thorough understanding of the safety profiles of medications used to manage this condition.

One of the key insights from the article is the systematic approach taken by the authors to analyze existing literature, which had previously only described individual studies without a meta-analytical perspective. This broader analysis allows for a more nuanced understanding of the safety outcomes related to antimuscarinic medications, specifically for patients aged 65 and older. By including a range of antimuscarinic agents such as oxybutynin, tolterodine, and solifenacin, the study provides valuable data on the potential cognitive implications of these drugs, which is particularly pertinent given the vulnerability of the elderly population to cognitive decline.

The findings indicate that while antimuscarinic medications can be effective in managing OAB symptoms, they are also associated with a variety of adverse events that may lead to treatment discontinuation. This aspect is crucial, as the cognitive side effects of these medications can exacerbate existing vulnerabilities in older adults, potentially leading to a decline in cognitive functions. The authors' systematic review underscores the importance of considering both efficacy and safety when prescribing these medications, particularly in the context of cognitive health.

Moreover, the article raises pertinent questions regarding the balance between the benefits of symptom relief and the risks of cognitive impairment. It suggests that healthcare providers must weigh these factors carefully, especially when treating older adults who may already be experiencing cognitive challenges. The meta-analysis thus serves as a call for more targeted research into the long-term effects of antimuscarinic drugs on cognitive functions, urging scholars and practitioners alike to prioritize patient safety and quality of life.

The article "Bladder antimuscarinics and cognitive decline in elderly patients" by Moga, Abner, Wu, and Jicha (Claudia Moga et al., 2007) presents a compelling investigation into the implications of antimuscarinic drug use on cognitive functions among older adults, particularly those aged 65 and above. The authors provide substantial evidence linking the initiation of antimuscarinic treatment for overactive bladder (OAB) to cognitive decline, which is a critical concern in the management of this condition in the elderly population.

The study's findings indicate a statistically significant correlation between the initiation of bladder antimuscarinics and deterioration in various cognitive functions. This association suggests that while these medications may alleviate urinary symptoms, they could concurrently exacerbate cognitive impairments, particularly in individuals with mild cognitive impairment (MCI). The authors emphasize that patients with MCI may exhibit increased sensitivity to the cognitive side effects of antimuscarinics, which raises important considerations for clinical decision-making.

Moreover, the article delves into specific cognitive outcomes that are biologically plausible in relation to antimuscarinic effects. This aspect of the research is particularly noteworthy as it not only establishes a statistical association but also seeks to elucidate the underlying mechanisms that may contribute to cognitive decline. The authors' approach to examining these mechanisms adds depth to the discourse surrounding the safety and efficacy of antimuscarinic drugs in the elderly. The article titled "Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)" by Griebeling et al. (L. Griebeling et al., 2000) provides

significant insights into the cognitive effects of pharmacotherapy for overactive bladder (OAB) in older adults. The study focuses on mirabegron, a beta-3 adrenergic agonist, as an alternative to traditional antimuscarinic agents, which have been associated with cognitive impairment in this population.

The authors present a well-structured investigation into the efficacy, safety, and tolerability of mirabegron in patients aged 65 years and older with OAB wet. The use of the Montreal Cognitive Assessment (MoCA) as a measure of cognitive function is a strong point of this study, as it provides a standardized method to evaluate cognitive changes over time. The findings indicate that mirabegron does not adversely affect cognitive function compared to placebo, suggesting it may be a safer option for managing OAB in elderly patients who are at risk for cognitive decline (L. Griebeling et al., 2000).

In contrast, the article also reviews the extensive literature surrounding the cognitive risks associated with anticholinergic medications, such as oxybutynin and tolterodine. The authors highlight that these medications have been linked to transient memory impairment, hallucinations, and a potential transition from normal cognition to mild cognitive impairment in older adults. This critical evaluation of antimuscarinic drugs underscores the importance of considering cognitive health when prescribing treatments for OAB in the elderly (L. Griebeling et al., 2000).

Moreover, the article emphasizes the need for clinicians to assess the risk-benefit profile of OAB treatments in older patients. The exploration of mirabegron as a viable alternative is timely, particularly in light of growing concerns regarding the cognitive side effects of antimuscarinics. The findings advocate for a shift in prescribing practices, promoting a more cautious approach to the use of anticholinergic medications in this vulnerable population.

CONCLUSION

The literature review presents a comprehensive analysis of the effects of antimuscarinic drugs on cognitive functions in elderly patients managing overactive bladder (OAB). The introduction sets the stage by highlighting the significant concerns regarding cognitive impairment associated with these medications,

particularly oxybutynin, which has been linked to memory deterioration (G Kay & Ebinger, 2008). The review systematically examines various studies that contribute to the understanding of how different antimuscarinic agents impact cognitive health in older adults.

(G Kay & Ebinger, 2008) provide foundational insights into the differential cognitive effects of antimuscarinic agents, establishing that while oxybutynin poses a risk for memory decline, darifenacin may offer a safer alternative due to its selectivity for the M3 receptor. (Yamada et al., 2012) further elaborate on the importance of bladder selectivity and the heightened risk of cognitive side effects due to increased blood-brain barrier permeability in elderly patients. (Tomaszewski, 2014) underscores the age-related changes in cholinergic receptor density that may exacerbate the cognitive side effects of antimuscarinic drugs, advocating for careful evaluation of individual medications.

(Chen et al., 2016) emphasize the high incidence of cognitive impairment associated with antimuscarinics in frail elderly patients, recommending lower starting doses to mitigate risks. (Claudia Moga et al., 2007) present evidence of a significant association between antimuscarinic initiation and cognitive decline, particularly in patients with mild cognitive impairment (MCI). The systematic review by (Martin Vouri et al., 2007) reinforces the need for a comprehensive understanding of the safety outcomes of these medications, highlighting the importance of evaluating the risk-benefit ratio.

(L. Griebeling et al., 2000) introduce mirabegron as a potential alternative to traditional antimuscarinics, suggesting that it may have a more favorable profile concerning cognitive function. Their findings support a shift in treatment paradigms for OAB in older adults, advocating for the careful selection of medications to balance efficacy with cognitive safety.

The literature collectively underscores the complexities involved in managing OAB in the elderly population, particularly regarding the cognitive risks associated with antimuscarinic therapy. The evidence suggests that while antimuscarinic drugs can effectively manage urinary symptoms, their potential impact on cognitive health warrants careful consideration and individualized treatment approaches. Ongoing

research is essential to further elucidate the relationship between these medications and cognitive functions, ultimately guiding clinical practice towards safer therapeutic options for this vulnerable demographic.

REFERENCES

G Kay, G. & Ebinger, U., 2008. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. ncbi.nlm.nih.gov

Yamada, S., Kuraoka, S., Osano, A., & Ito, Y., 2012. Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of In Vivo Drug-Receptor Binding. ncbi.nlm.nih.gov

Tomaszewski, J., 2014. Postmenopausal overactive bladder. ncbi.nlm.nih.gov

Chen, J. L., Chen, S. F., Jiang, Y. H., & Kuo, H. C., 2016. Practical points in the medical treatment of overactive bladder and nocturia in the elderly. ncbi.nlm.nih.gov

Claudia Moga, D., L. Abner, E., Wu, Q., & A. Jicha, G., 2007. Bladder antimuscarinics and cognitive decline in elderly patients.

Martin Vouri, S., D. Kebodeaux, C., M. Stranges, P., & F. Teshome, B., 2007. Adverse Events and Treatment Discontinuations of Antimuscarinics for the Treatment of Overactive Bladder in Older Adults: A Systematic Review and Meta-Analysis.

L. Griebeling, T., L. Campbell, N., Mangel, J., Staskin, D., Herschorn, S., Elsouda, D., & R. Schermer, C., 2000. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR).

Claudia Moga, D., L. Abner, E., Wu, Q., & A. Jicha, G., 2007. Bladder Antimuscarinics and Cognitive Decline in Elderly Patients.